NCT00002529 arm group b6f569df1b3a2ca88f0b2798e82bf28a [clinicaltrials_resource:NCT00002529/arm-group/b6f569df1b3a2ca88f0b2798e82bf28a]
doxorubicin hydrochloride [clinicaltrials_resource:33dea93e97843c2e9a11ed18882495c6]cyclophosphamide [clinicaltrials_resource:3ed5f802cff4f8d396e0df2c42e39f98]epirubicin hydrochloride [clinicaltrials_resource:bfcb783c02b006e9fb5afa975aa5e531]tamoxifen citrate [clinicaltrials_resource:c865640863998a60f3885b9f11e657cf]clinicaltrials:NCT00002529
arm group [clinicaltrials_vocabulary:arm-group]
NCT00002529 arm group b6f569df1b3a2ca88f0b2798e82bf28a [clinicaltrials_resource:NCT00002529/arm-group/b6f569df1b3a2ca88f0b2798e82bf28a]
Bio2RDF identifier
NCT00002529/arm-group/b6f569df1b3a2ca88f0b2798e82bf28a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... f569df1b3a2ca88f0b2798e82bf28a
description [clinicaltrials_vocabulary:description]
AC for 4 cycles with concurrent tamoxifen for 5 years
identifier
clinicaltrials_resource:NCT00002529/arm-group/b6f569df1b3a2ca88f0b2798e82bf28a
title
NCT00002529 arm group b6f569df1b3a2ca88f0b2798e82bf28a
@en
type
label
NCT00002529 arm group b6f569df ...... 569df1b3a2ca88f0b2798e82bf28a]
@en